Liraglutide Protects the Diabetic Heart by Blocking a Type of Cell Death Called Ferroptosis

What the researchers found

Liraglutide (200 μg/kg/day for 8 weeks) improved glucose metabolism, cardiac remodeling, and heart function while reducing lipid peroxidation and ferroptosis in Goto-Kakizaki diabetic rats. The drug upregulated ferroptosis-related protective proteins including NRF2 (both cytoplasmic and nuclear forms), GPX4, and FTH-1.

In cell culture, high glucose triggered lipid reactive oxygen species production, reduced mitochondrial mass, and lowered ferroptosis-protective proteins — effects that were reversed by liraglutide treatment. Silencing NRF2 with siRNA abolished liraglutide's protective effects, confirming NRF2 as the key mediator of its anti-ferroptotic action.

Why it matters

Ferroptosis is increasingly recognized as a driver of organ damage in diabetes, but targeted treatments are lacking. This study suggests that liraglutide — already FDA-approved and widely prescribed for diabetes — may provide heart protection through an entirely new mechanism beyond blood sugar control, potentially expanding the rationale for its use in diabetic patients at risk of heart disease.

How the study worked

The in vivo model used Goto-Kakizaki (GK) rats, a spontaneous type 2 diabetes strain, treated with subcutaneous liraglutide at 200 μg/kg/day for 8 weeks. Cardiac function, glucose metabolism, lipid peroxidation markers, and ferroptosis-related protein levels were assessed. In vitro experiments used H9C2 rat heart cells exposed to high glucose with or without liraglutide, NRF2 siRNA knockdown, and the ferroptosis inhibitor ferrostatin-1 (Fer-1).

What this study cannot tell us

This was an animal and cell culture study — the findings have not been confirmed in human patients with diabetic cardiomyopathy. The Goto-Kakizaki rat model does not perfectly replicate human type 2 diabetes. Specific quantitative outcomes (effect sizes, statistical values) for cardiac function improvements were not detailed in the abstract. The 8-week treatment duration may not reflect long-term effects.

How to read the evidence

This is a preclinical study combining animal experiments (GK rats) with in vitro cell culture work. While it provides mechanistic insight with NRF2 knockdown confirmation, the findings have not been validated in human subjects.

When this study was published

Published in 2025, this is a very recent study reflecting current interest in ferroptosis as a therapeutic target and the expanding understanding of GLP-1 agonist mechanisms beyond glycemic control.

The bigger picture

GLP-1 receptor agonists like liraglutide have already shown cardiovascular benefits in large clinical trials, but the mechanisms behind this protection are not fully understood. This study adds ferroptosis suppression via NRF2 as a new mechanistic explanation, joining a growing body of evidence that GLP-1 drugs do far more than lower blood sugar — they may directly protect tissues from multiple forms of damage.

Questions still open

• Does liraglutide's anti-ferroptotic effect translate to measurable cardiac protection in human diabetic patients?
• Do other GLP-1 receptor agonists like semaglutide share this NRF2-mediated ferroptosis suppression in heart tissue?
• Could targeting NRF2 directly be a more potent strategy for preventing ferroptosis in diabetic cardiomyopathy?

Common questions

Read the original research

Liraglutide suppresses ferroptosis by upregulation NRF2 in type 2 diabetic cardiomyopathy.

Peptides, 192, 171429

Citation

Chen, Xuepin; Wang, Tianying; Gao, Yan; Wang, Guo An; Guan, Jun; Dai, Hongyan. (2025). Liraglutide suppresses ferroptosis by upregulation NRF2 in type 2 diabetic cardiomyopathy.. Peptides, 192, 171429. https://doi.org/10.1016/j.peptides.2025.171429